OT mobile menu

Search form


Leukemia & Lymphoma

LLS Precision Medicine Trial May Change Treatment Paradigm for AML Patients

The Leukemia & Lymphoma Society will head up the Beat AML Master Trial, which will use a precision medicine protocol under the support and guidance from the FDA. Image © Minerva Studio/Shutterstock.com 

Leukemia & Lymphoma

Researchers have identified two distinct stem cell–like populations from which relapse can arise in AML patients, which may help clinicians identify who will and won't respond to standard chemotherapy.

ODAC approval of Novartis' CAR T-Cell therapy paves the way for its FDA approval as a commercially available treatment for B-cell ALL.

A new study in JCO suggests that genetic variations within AML patients with CD33 may predict their response to gemtuzumab ozogamicin.

A follow-up analysis of the CheckMate-205 clinical trial found that nivolumab was associated with durable response rates in adults with relapsed or refractory Hodgkin lymphoma after ASCT.

Researchers have uncovered how mutations in a protein network drive several high-risk leukemias, offering new prospects for novel therapies.

Lenalidomide plus rituximab induction therapy followed by maintenance appears to provide favorable activity and a tolerable safety profile in follicular lymphoma patients who are double-refractory or had early relapse after initial diagnosis.

Anti-CD19 CAR T-cell therapy may benefit patients with aggressive B-cell non-Hodgkin lymphoma who have relapsed or are refractory to standard therapy.


Subscribe to Leukemia & Lymphoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.